肝硬化顽固性腹水的治疗  

Management of refractory ascites in liver cirrhosis

作　　者：李岚[1] 厉有名[1] 

机构地区：[1]浙江大学医学院附属第一医院消化内科,杭州310003

出　　处：《中国实用内科杂志》2013年第9期676-678,共3页Chinese Journal of Practical Internal Medicine

摘　　要：肝硬化顽固性腹水是肝硬化发展到晚期的严重并发症,预后差。目前常用的治疗方法包括限制钠盐摄入、白蛋白和利尿剂的使用、腹腔穿刺放液、经颈静脉肝内门体分流术、腹水浓缩回输等。近年来,特利加压素、血管加压素V2受体拮抗剂、米可君、非选择性β受体阻滞剂等一些药物逐渐被用于控制顽固性腹水,取得了一定的治疗效果。该文就肝硬化顽固性腹水的常用治疗和最新进展做一介绍。Refractory ascites is a common complication of liver cirrhosis associated with a poor prognosis. The current medi-cal managements of refractory ascites include sodium restriction, a combination of albumin and diuretic, large-volume para-centesis, transjugular intrahepatic portosystcmic shunt, and ascites concentration-reinfusion. Potential new treatment options for refractory ascites include the use of tedipressin, vasopressin type 2 receptor antagonists, midodrinc, and nonselective b- blocker, all of which could possibly improve the management of ascites. This paper makes an introduction of current manage-ment and novel therapeutic strategies for refractory ascites.

关 键 词：肝硬化 顽固性腹水 腹腔穿刺放液 经颈静脉肝内门体分流术 腹水浓缩回输 

分 类 号：R575.2[医药卫生—消化系统]